TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbH;Ganymed Pharmaceuticals GmbH
发明人:
Sahin, Ugur,Türeci, Özlem,Mitnacht-Kraus, Rita,Jacobs, Stefan Denis,Utsch, Magdalena Jadwiga,Heinz, Cornelia Adriana Maria,Stadler, Christiane Regina
申请号：
NZ72534713
公开号：
NZ725347A
申请日:
2013.05.21
申请国别(地区):
NZ
年份:
2018
代理人:
摘要：
The present invention provides a combination therapy combination therapy comprising an antibody having the ability of binding to CLDN18.2 with an agent stabilizing or increasing expression of CLDN18.2 for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
